by Peter Ciszewski | Sep 25, 2017
David G. Birch, PhD, Chief Scientific and Executive Officer and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, Retina Foundation of the Southwest discusses X-Linked Retinoschisis (XLRS). X-linked retinoschisis (XLRS) is an inherited early onset...
by Peter Ciszewski | Sep 25, 2017
Treatments for diabetic retinopathy with new mechanisms of action and new options for age-related macular degeneration will be garnering attention here at the American Society of Retina Specialists (ASRS) 2017 Annual Meeting. Although current antivascular endothelial...
by Peter Ciszewski | Sep 25, 2017
David G. Birch, PhD, Chief Scientific and Executive Officer and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, Retina Foundation of the Southwest discusses the current clinical trial for patients suffering from X-linked retinoschisis (XLRS)....
by Peter Ciszewski | Sep 25, 2017
Ambitious targets to disseminate best practice and improve access to care, alongside measurable parameters to determine progress, are essential if the substantial disparities in cancer outcomes between different regions and countries in Europe are to be closed up,...
by Peter Ciszewski | Sep 25, 2017
New data are set to change the paradigm for the first-line treatment of advanced renal cell carcinoma (RCC), after a phase 3 trial showed significantly improved overall survival (OS) with immunotherapy in comparison to standard care with sunitinib (Sutent,...
